STOCK TITAN

Provectus Biopharm (PVCT) CEO converts 8% note into equity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities related to prior financing arrangements. An 8% unsecured convertible promissory note converted into 18,876 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 188,760 shares of common stock. Following these conversions, Pershing held 2,793,109 shares of common stock directly, with no remaining derivative position from this note.

Positive

  • None.

Negative

  • None.
Insider Pershing Edward
Role CEO
Type Security Shares Price Value
Exercise 8% Unsecured Convertible Promissory Note 0 $0.00 --
Exercise Series D-1 Convertible Preferred Stock 18,876 $0.00 --
Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct, null); Series D-1 Convertible Preferred Stock — 2,793,109 shares (Direct, null)
Footnotes (1)
  1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On May 07, 2026, the 2025 Note was converted into 18,876 shares of Series D-1 Preferred Stock.
Common shares acquired 188,760 shares Common stock received from Series D-1 Preferred conversion
Preferred shares from note 18,876 shares Series D-1 Convertible Preferred Stock issued from 2025 Note
Post-transaction common holdings 2,793,109 shares Common stock directly held after conversions
Note conversion price $2.862 per share Conversion price of 2025 Note into Series D-1 Preferred
Preferred-to-common ratio 10:1 Each Series D-1 Preferred converts into 10 common shares
Note interest rate 8% Interest rate on unsecured convertible promissory note
Series D-1 Convertible Preferred Stock financial
"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"
8% Unsecured Convertible Promissory Note financial
"The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note"
convertible financial
"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"
A convertible is a type of investment that starts as a loan or preferred stake (like a bond or preferred share) but can be exchanged for common shares of the company at a set price or under certain conditions. It matters to investors because it offers a mix of steady income and downside protection like a loan, plus the upside of stock ownership if the company does well—similar to holding a coupon that you can trade for a full ticket if the event becomes valuable.
Certificate of Designation regulatory
"in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock"
A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.
2025 Financing financial
"The 2025 Note was issued pursuant to the Issuer's 2025 Financing"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pershing Edward

(Last)(First)(Middle)
800 S. GAY STREET,
SUITE 1610

(Street)
KNOXVILLE TENNESSEE 37929

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
8% Unsecured Convertible Promissory Note$2.86205/07/2026M$50,00005/07/202505/07/2026Series D-1 Convertible Preferred Stock(3)(4)18,876$0$1,015,000D
Series D-1 Convertible Preferred Stock(1)05/07/2026M18,87605/07/2026 (2)Common Stock188,760$02,793,109D
Explanation of Responses:
1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
4. On May 07, 2026, the 2025 Note was converted into 18,876 shares of Series D-1 Preferred Stock.
/s/ Edward Pershing05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PVCT CEO Edward Pershing report on this Form 4?

Edward Pershing reported exercising derivative securities, converting an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock and then into common stock. This sequence turned debt into equity, increasing his directly held common shares without any reported share sales.

How many PVCT common shares did the CEO receive from the conversions?

The conversions resulted in 188,760 shares of PVCT common stock. These came from 18,876 shares of Series D-1 Convertible Preferred Stock, with each preferred share convertible into 10 common shares according to the terms described in the filing footnotes.

What were the terms of the 8% unsecured convertible promissory note for PVCT?

The 8% unsecured convertible promissory note, referred to as the 2025 Note, was convertible into Series D-1 Convertible Preferred Stock at $2.862 per share. The note’s principal and interest automatically converted into 18,876 preferred shares twelve months after its issue date.

When did the PVCT 2025 Note convert into Series D-1 Preferred Stock?

On May 7, 2026, the 2025 Note converted into 18,876 shares of Series D-1 Convertible Preferred Stock. This automatic conversion followed the note’s terms, which provided for conversion twelve months after its issue date into preferred shares at $2.862 per share.

What is the conversion ratio of PVCT Series D-1 Preferred into common stock?

Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of PVCT common stock. The filing states this fixed ratio, which was applied when 18,876 preferred shares became 188,760 common shares held directly by the reporting person.

Does the PVCT Series D-1 Preferred automatically convert into common stock at a future date?

Yes. The Series D-1 Convertible Preferred Stock will automatically convert into common stock on December 31, 2028, unless converted earlier under its terms. This automatic conversion date is specified in the Series D-1 Certificate of Designation referenced in the footnotes.